Month: January 2023

Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the...

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast...

Microbot Medical Welcomes Distinguished Interventional Cardiologist and Early Adopter of Endovascular Robotics to its Next “Access-Ability Live by MBOT” Webinar Series

Dr. Giora Weisz, a Practicing Interventional Cardiologist and Clinical Researcher who was One of the Early Users of Robotic-Enhanced Coronary...

Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers

Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such...

QHSLab, Inc. Reiterates its 2022 Projection of a $7.5 Billion Addressable Market for its Integrated Service Program (ISP) Digital Health Solution Designed For Primary Care

QHSLab reports that commercialization and the path to profitability is in clear sight, which is an unfamiliar acknowledgment for investors...

error: Content is protected !!